Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 6mg/2mL prefilled syringe
- 12mg/4mL prefilled syringe
Paroxysmal Supraventricular Tachycardia
Indicated for conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome)
Adenocard: 6 mg IVP over 1-3 seconds (maybe given IO) followed by rapid flush with 20 mL NS, if no conversion within 1-2 minutes give 12 mg IVP, repeat a second time if necessary (30 mg total)
Dosing considerations
- When clinically advisable for PSVT, appropriate vagal maneuvers (eg, Valsalva maneuver), should be attempted prior to adenosine administration
Stress Testing (Diagnostic)
Indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately
Adenoscan: 140 mcg/kg/min IV infusion for 6 min
Other Indications & Uses
Off-label: Sustained ventricular tachycardia (SVT)
Dosage Forms & Strengths
injectable solution
- 6mg/2mL prefilled syringe
- 12mg/4mL prefilled syringe
Paroxysmal Superventricular Tachycardia (per ACLS)
<50 kg: 0.05 to 0.1 mg/kg rapid IVP over 1-3 seconds or IO, no more than 0.3 mg/kg/dose, followed by rapid flush with > 5 mL 0.9% NaCl
If necessary may give 2nd dose of 0.2 mg/kg IVP/IO, not to exceed cumulative dose of 12 mg
Elderly may experience more adverse effects from adenosine; they may be more sensitive
PSVT (Adenocard)
6 mg IVP over 1-3 seconds (maybe given IO) followed by rapid flush with 20 mL NS, if no conversion within 1-2 minutes give 12 mg IVP, repeat a second time if necessary (30 mg total)
Adenoscan (Diagnostic)
Stress testing (Adenoscan): 140 mcg/kg/min IV infusion for 6 min
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (1)
- ponesimod
ponesimod, adenosine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Consult cardiologist if considering treatment. Coadministration of ponesimod with drugs that decrease HR may have additive effects on decreasing HR and should generally not be initiated in these patients.
Monitor Closely (7)
- dipyridamole
dipyridamole increases levels of adenosine by decreasing metabolism. Use Caution/Monitor.
- green tea
green tea decreases effects of adenosine by unspecified interaction mechanism. Use Caution/Monitor. (Theoretical interaction).
- hawthorn
hawthorn increases effects of adenosine by pharmacodynamic synergism. Use Caution/Monitor.
- nicotine inhaled
nicotine inhaled increases effects of adenosine by unknown mechanism. Use Caution/Monitor. Adenosine associated tachycardia and chest pain.
- nicotine intranasal
nicotine intranasal increases effects of adenosine by unknown mechanism. Use Caution/Monitor. Adenosine associated tachycardia and chest pain.
- sevelamer
sevelamer decreases levels of adenosine by increasing elimination. Use Caution/Monitor.
- theophylline
theophylline decreases effects of adenosine by pharmacodynamic antagonism. Use Caution/Monitor.
Minor (18)
- acebutolol
acebutolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- atenolol
atenolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- betaxolol
betaxolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- bisoprolol
bisoprolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- caffeine
caffeine decreases effects of adenosine by pharmacodynamic antagonism. Minor/Significance Unknown.
- carvedilol
carvedilol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- celiprolol
celiprolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- esmolol
esmolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- labetalol
labetalol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- lily of the valley
adenosine, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.
- metoprolol
metoprolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- nadolol
nadolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- nebivolol
nebivolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- penbutolol
penbutolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- pindolol
pindolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- propranolol
propranolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- sotalol
sotalol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
- timolol
timolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.
Adverse Effects
>10%
Flushing (18%)
Dyspnea (12%)
1-10%
Chest pressure (7%)
HA (2%)
Lightheadedness (2%)
Dizziness (1%)
Tingling in arms (1%)
Numbness (1%)
Nausea (3%)
<1%
Hypotension
Palpitations
Apprehension
Head pressure
Chest pain
Hyperventilation
Blurred vision
Burning sensation
Heaviness in arms, neck and back pain
Metallic taste
Tightness in throat
Pressure in groin
Sweating
Post Marketing (undefined)
Prolonged asystole
Ventricular tachycardia
Venricular fibrillation
Transient increase in blood pressure
Bradycardia
Atrial fibrillation
Cardiac failure
Infusion site pain
Hypersensitivity
Torsades de Pointes
Seizure
Bronchospasm
Warnings
Contraindications
Hypersensitivity
2nd or 3rd degree AV block (except those on pacemakers)
Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker)
Adenoscan: Contraindicated in bronchoconstrictive or bronchospastic lung disease (eg, asthma)
Cautions
Symptomatic bradycardia, cardiac arrest, heart block, heart transplant patients, HTN, hypotension, MI, proarrhythmic events, unstable angina
Adenocard: Caution with bronchoconstrictive or bronchospastic lung disease (eg, asthma)
Cerebrovascular accident hemorrhagic and ischemic cerebrovascular accidents reported; hemodynamic effects of adenosine including hypotension or hypertension possibly associated with these adverse reactions
Nucleoside transport inhibitors (eg, dipyridamole) and potentiate the vasoactive effects of adenosine; withhold for 5 half-lives before adenosine administration
Methylxanthines (eg, caffeine, theophylline) are adenosine receptor antagonists and inhibit adenosine’s vasoactive effects; withhold methylxanthines for 5 half-lives before adenosine administration
New-onset or recurrence of convulsive seizures reported following adenosine; some seizures are prolonged and require emergent anticonvulsive management; aminophylline may increase risk of seizures associated with adenosine; methylxanthine use not recommended in patients who experience seizures in association with adenosine administration
Dyspnea, throat tightness, flushing, erythema, rash, and chest discomfort reported that may require symptomatic treatment; resuscitative measures may be necessary if symptoms progress; have trained personnel and treatment available during treatment
Arrhythmia at time of cardioversion (Adenocard): Ventricular fibrillation reported following administration, including both resuscitated and fatal events; in most instances, these cases were associated with the concomitant use of digoxin and, less frequently with digoxin and verapamil
Risk for myocardial infarction and death
- Avoid use for cardiac nuclear stress tests in patients with signs or symptoms of acute myocardial ischemia (eg, unstable angina, cardiovascular instability); use may increase risk of fatal MI
- Screen all nuclear stress test candidates for risks
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Potential for serious adverse reactions in nursing infants; decision to interrupt nursing after administration of adenosine or not should take into account importance of drug to mother
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
PSVT: Slows conduction through AV node and interrupts AV reentry pathways, which restore normal sinus symptoms
Stress testing: A2A adenosine receptor agonist; activation of the A2A adenosine receptor produces coronary vasodilation and increases coronary blood flow
Pharmacokinetics
Half-life: <10 sec
Duration: <10 sec
Onset: 20-30 sec
Metabolism: Blood and tissue; deaminated to inosine and subsequently to hypoxanthine; adenosine also undergoes phosphorylation to adenosine monophosphate (AMP) within blood cells
Metabolites: Inosine, hypoxanthine, AMP (inactive)
Total body clearance: 30 sec
Administration
IV Compatibilities
Solution: dextrose 5% in LR, D5W, LR, NS
IV Administration
Adenocard: given as a rapid injection (1-3 sec) by peripheral IV route directly into vein or into IV line close (proximal) to patient and is followed by rapid NS flush after each injection (20 mL for adults, 5 mL or more for pediatrics)
Place patient in mild reverse Trendelenburg position before giving drug
Record rhythm strip during administration
Draw up (separate syringes)
- Adenosine dose
- Flush
- Attach both syringes to IV injection port nearest to patient
Clamp IV tubing above injection port
Avoid drug traveling retrograde
Push adenosine as fast as possible (1-3 sec)
While keeping pressure on adenosine syringe plunger, push NS flush as fast as possible
Unclamp IV tubing
Preferred method using a stopcock
- Have adenosine in one port and NS flush in other port
- Simply open stopcock to adenosine and push
- Close stopcock and open port to NS and push
- Eliminates possibility of adenosine traveling retrograde
May be given via central line or intraosseus
Adenoscan: given by continuous peripheral IV infusion for 6 minutes
Storage
Store at controlled room temperature of 15-30°C
Do not refrigerate; possible crystal formation
Solution must be clear prior to administration
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| adenosine intravenous - | 3 mg/mL vial |  | |
| adenosine intravenous - | 3 mg/mL solution |  | |
| adenosine intravenous - | 3 mg/mL solution |  | |
| adenosine intravenous - | 3 mg/mL vial |  | |
| adenosine intravenous - | 3 mg/mL vial |  | |
| adenosine intravenous - | 3 mg/mL vial |  | |
| adenosine intravenous - | 3 mg/mL vial |  | |
| adenosine intravenous - | 3 mg/mL vial |  | |
| adenosine intravenous - | 3 mg/mL solution |  | |
| adenosine intravenous - | 3 mg/mL solution |  | |
| adenosine intravenous - | 3 mg/mL vial |  | |
| adenosine intravenous - | 3 mg/mL vial |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
adenosine intravenous
NO MONOGRAPH AVAILABLE AT THIS TIME
USES: Consult your pharmacist.
HOW TO USE: Consult your pharmacist.
SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Consult your pharmacist.
DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: No monograph available at this time.
MISSED DOSE: Consult your pharmacist.
STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Information last revised July 2016. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
